{"id":868590,"date":"2025-07-10T16:29:14","date_gmt":"2025-07-10T20:29:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/"},"modified":"2025-07-10T16:29:14","modified_gmt":"2025-07-10T20:29:14","slug":"jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","title":{"rendered":"Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong><br \/>\n          <em>Nasdaq compliance follows positive upward trend in Company\u2019s Stock Price\u00a0<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">Jupiter, Florida, July  10, 2025  (GLOBE NEWSWIRE) &#8212; Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (\u201cJupiter\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing JOTROL<sup>\u2122<\/sup>, a patented resveratrol-based platform, today announced it has regained compliance with the Nasdaq Stock Market (\u201cNasdaq\u201d) continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. This update was disclosed in the Company\u2019s Current Report on Form 8-K filed on July 10, 2025.<\/p>\n<p align=\"justify\">On July 9, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of July 3, 2025 the Company\u2019s common stock has maintained an average closing share price of at least $1.00 for a period of thirteen (13) days (June 18, 2025 to July 8, 2025). The Company\u2019s shares are no longer considered to be below the minimum bid price requirement of Rule 5550(a)(2), and as a result the Company has regained compliance with the Nasdaq continued listing standard. Nasdaq now considers this matter closed.<\/p>\n<p>\n        <strong>About Jupiter Neurosciences, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia<sup>\u2122\u00a0<\/sup>product line. Both efforts are powered by JOTROL<sup>\u2122<\/sup>, Jupiter\u2019s proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company\u2019s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson\u2019s disease, includeing indications such as Alzheimer\u2019s Disease, Mucopolysaccharidoses Type I, Friedreich\u2019s Ataxia, and MELAS. More information may be found on the Company\u2019s website\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZoCDZaRznZW3jmmZD9JtnIA_UDBg0-U17NzxHi2vb7Rol6_dgZgovD8KXwXI7EApvlG8OymQUCYo9m2k6_CCIN4G1UcLnX2iuvyvU0U5TwkgXvj5SN8C_dIMb7W0kUQgAWRu1FNq6sgFBphs1ThWn9pFg0geskVZYpJ5th0mntM5Bzy4M_MT1XpZb0WTDcJynbaqATZ2-23GcXffn9zqoToYc0Ac9YtOvmhMD9MNWy_pYHLkWoqXty947Xst4FIdHyNMjG_4uBeubwlhIq3vXZpZgLS-gSZLhtVUZqAs4km1-4Ccd8dKM0PRIw12mhyT\" rel=\"nofollow\" target=\"_blank\">www.jupiterneurosciences.com<\/a>.<\/p>\n<p>\n        <strong>FORWARD-LOOKING STATEMENTS<\/strong>\n      <\/p>\n<p align=\"justify\">Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company\u2019s current expectations, including the Company\u2019s ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as \u201capproximates,\u201d \u201cbelieves,\u201d \u201chopes,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cmay\u201d or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company\u2019s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company\u2019s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.<\/p>\n<p>\n        <strong>Contact: <\/strong><br \/>\n        <br \/>Dave Gentry<br \/>RedChip Companies, Inc.<br \/>1-407-644-4256<br \/>1-800-RED-CHIP (733-2447)<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NzFu9V6UpRp-aIRcB8AmiGQrjjgdp8SvAbZhAiwP6fU_moaq0sBt09FS9Xa0WCW3uv8NKFWYwbtgWeBwxlzwUAssBLqPFu1wge-Z8qPaGAU=\" rel=\"nofollow\" target=\"_blank\">JUNS@redchip.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MjYwOSM3MDQyNDM1IzUwMDEzMDYzOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/N2VkYjRjNjYtZGRmYS00YWFhLWIxM2ItMDAyNjE0NTBhNTkyLTUwMDEzMDYzOS0yMDI1LTA3LTEwLWVu\/tiny\/Jupiter-Neurosciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nasdaq compliance follows positive upward trend in Company\u2019s Stock Price\u00a0 Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) &#8212; Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (\u201cJupiter\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing JOTROL\u2122, a patented resveratrol-based platform, today announced it has regained compliance with the Nasdaq Stock Market (\u201cNasdaq\u201d) continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. This update was disclosed in the Company\u2019s Current Report on Form 8-K filed on July 10, 2025. On July 9, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of July 3, 2025 the Company\u2019s common stock has maintained an average closing share price of at least $1.00 for a period &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-868590","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Nasdaq compliance follows positive upward trend in Company\u2019s Stock Price\u00a0 Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) &#8212; Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (\u201cJupiter\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing JOTROL\u2122, a patented resveratrol-based platform, today announced it has regained compliance with the Nasdaq Stock Market (\u201cNasdaq\u201d) continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. This update was disclosed in the Company\u2019s Current Report on Form 8-K filed on July 10, 2025. On July 9, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of July 3, 2025 the Company\u2019s common stock has maintained an average closing share price of at least $1.00 for a period &hellip; Continue reading &quot;Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-10T20:29:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MjYwOSM3MDQyNDM1IzUwMDEzMDYzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement\",\"datePublished\":\"2025-07-10T20:29:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\"},\"wordCount\":507,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MjYwOSM3MDQyNDM1IzUwMDEzMDYzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\",\"name\":\"Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MjYwOSM3MDQyNDM1IzUwMDEzMDYzOQ==\",\"datePublished\":\"2025-07-10T20:29:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MjYwOSM3MDQyNDM1IzUwMDEzMDYzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MjYwOSM3MDQyNDM1IzUwMDEzMDYzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","og_locale":"en_US","og_type":"article","og_title":"Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - Market Newsdesk","og_description":"Nasdaq compliance follows positive upward trend in Company\u2019s Stock Price\u00a0 Jupiter, Florida, July 10, 2025 (GLOBE NEWSWIRE) &#8212; Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (\u201cJupiter\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing JOTROL\u2122, a patented resveratrol-based platform, today announced it has regained compliance with the Nasdaq Stock Market (\u201cNasdaq\u201d) continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. This update was disclosed in the Company\u2019s Current Report on Form 8-K filed on July 10, 2025. On July 9, 2025, the Company received confirmation from the Listing Qualifications Department of Nasdaq that as of July 3, 2025 the Company\u2019s common stock has maintained an average closing share price of at least $1.00 for a period &hellip; Continue reading \"Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-10T20:29:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MjYwOSM3MDQyNDM1IzUwMDEzMDYzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement","datePublished":"2025-07-10T20:29:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/"},"wordCount":507,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MjYwOSM3MDQyNDM1IzUwMDEzMDYzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/","name":"Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MjYwOSM3MDQyNDM1IzUwMDEzMDYzOQ==","datePublished":"2025-07-10T20:29:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MjYwOSM3MDQyNDM1IzUwMDEzMDYzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MjYwOSM3MDQyNDM1IzUwMDEzMDYzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jupiter-neurosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=868590"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868590\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=868590"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=868590"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=868590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}